Literature DB >> 12773976

Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma.

Hideaki Shimada1, Yoshihiro Nabeya, Shin-ichi Okazumi, Hisahiro Matsubara, Tooru Shiratori, Yoshio Gunji, Susumu Kobayashi, Hideki Hayashi, Takenori Ochiai.   

Abstract

BACKGROUND: Increased preoperative serum squamous cell carcinoma antigen (SCC-Ag) concentrations have been found to be associated with advanced stage and poor prognosis in lung and cervical cancers. Because little was known about the significance of SCC-Ag concentration in patients with esophageal cancer, the aim of this study was to analyze the clinicopathologic significance of SCC-Ag in patients with esophageal SCC. PATIENTS AND METHODS. Preoperative SCC-Ag concentration was measured with enzyme-linked immunosorbent assay in 309 patients with primary esophageal SCC. All patients underwent curative radical surgery without any preoperative therapy. In 215 of 309 patients, carcinoembryonic antigen (CEA) was also measured to compare clinical significance of CEA with that of SCC-Ag. The prognostic significance for survival of SCC-Ag concentrations was studied with multivariate analysis with Cox proportional hazards model.
RESULTS: The SCC-Ag concentration and the positivity rate of SCC-Ag were significantly elevated in patients associated with tumor progression. Statistically significant differences in SCC-Ag concentrations and SCC-Ag positivity rates were observed depending on tumor size, tumor depth, lymph node status, and distant metastasis. Although CEA was not a prognostic factor (P =.21), a high SCC-Ag concentration was a significant prognostic factor (P <.01). Multivariate analyses indicated that T factor had the best predictive power, but SCC-Ag concentration contained additional, independent prognostic information.
CONCLUSION: Our findings suggest that preoperative serum SCC-Ag concentrations might provide a predictive information for tumor progression and survival in patients with esophageal SCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773976     DOI: 10.1067/msy.2003.139

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  49 in total

Review 1.  SERPINB3 and B4: From biochemistry to biology.

Authors:  Yu Sun; Namratha Sheshadri; Wei-Xing Zong
Journal:  Semin Cell Dev Biol       Date:  2016-09-13       Impact factor: 7.727

2.  Cytoplasmic HDPR1 is involved in regional lymph node metastasis and tumor development via beta-catenin accumulation in esophageal squamous cell carcinoma.

Authors:  Jian Hou; En-Min Li; Jin-Hui Shen; Zhi-Yong Wu; Xiu-E Xu; Jian-Yi Wu; Jian Shen; Ming-Zhou Guo; Li-Yan Xu
Journal:  J Histochem Cytochem       Date:  2011-04-27       Impact factor: 2.479

3.  NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.

Authors:  Yoko Oshima; Hideaki Shimada; Satoshi Yajima; Tatsuki Nanami; Kazuyuki Matsushita; Fumio Nomura; Osamu Kainuma; Nobuhiro Takiguchi; Hiroaki Soda; Takeshi Ueda; Toshihiko Iizasa; Naoto Yamamoto; Hiroshi Yamamoto; Matsuo Nagata; Sana Yokoi; Masatoshi Tagawa; Seiko Ohtsuka; Akiko Kuwajima; Akihiro Murakami; Hironori Kaneko
Journal:  J Gastroenterol       Date:  2015-04-24       Impact factor: 7.527

4.  Prognostic significance of platelet × C-reactive protein multiplier in patients with esophageal squamous cell carcinoma.

Authors:  Yuji Shishido; Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Kozo Miyatani; Tomoyuki Matsunaga; Manabu Yamamoto; Yoji Fukumoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-08-30       Impact factor: 2.549

5.  The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma.

Authors:  Fumiaki Shiratori; Masaaki Ito; Satoshi Yajima; Takashi Suzuki; Yoko Oshima; Tatsuki Nanami; Kimihiko Funahashi; Hideaki Shimada
Journal:  Esophagus       Date:  2019-02-18       Impact factor: 4.230

Review 6.  Molecular alterations and clinical relevance in esophageal squamous cell carcinoma.

Authors:  Li Shang; Mingrong Wang
Journal:  Front Med       Date:  2013-09-03       Impact factor: 4.592

7.  Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.

Authors:  Jun Dong; Bo-hang Zeng; Li-hua Xu; Jun-ye Wang; Man-zhi Li; Mu-sheng Zeng; Wan-li Liu
Journal:  J Transl Med       Date:  2010-09-03       Impact factor: 5.531

Review 8.  From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma.

Authors:  Yataro Daigo; Yusuke Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-02-24

9.  Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer.

Authors:  Hideaki Shimada; Akiko Kagaya; Tooru Shiratori; Fumio Nomura; Masaki Takiguchi; Hisahiro Matsubara; Takaki Hiwasa
Journal:  J Gastroenterol       Date:  2009-05-01       Impact factor: 7.527

10.  Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Tooru Shiratori; Mari Yasuraoka; Akiko Kagaya; Mari Kuboshima; Fumio Nomura; Masaki Takiguchi; Takenori Ochiai; Hisahiro Matsubara; Takaki Hiwasa
Journal:  BMC Cancer       Date:  2009-07-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.